28
33
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T80131 | C5a Anaphylatoxin (human) | Complement System | |
C5a Anaphylatoxin (human) is a pro-inflammatory peptide that functions as a leukocyte chemoattractant, utilized in researching inflammation and immune responses, including allergic asthma [1] [2]. | |||
T80265 | C5a Receptor agonist, mouse, human | Complement System | |
C5a Receptor Agonist (mouse, human) is a bioactive peptide derived from the C-terminus of the complement fragment 5 anaphylatoxin (C5a), functioning as an agonist for the C5a receptor. This peptide plays a role in mediat... | |||
T9915 | Eculizumab | Complement System | |
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | |||
T17250 | W-54011 | ROS , Complement System | |
W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and g... | |||
T82797 | C5aR1 antagonist peptide | ||
C5aR1 antagonist peptide, a biologically active linear peptide originating from the C-terminus of the chemokine complement fragment 5 anaphylatoxin (C5a), inhibits C5a binding and activity at human and rat C5a receptors.... | |||
T73262 | C5aR-IN-3 | ||
C5aR-IN-3, a potent C5aR inhibitor, holds potential for inflammation disease research due to its ability to counteract increased C5a levels, which are linked to autoimmune and inflammatory disorders. | |||
T73261 | C5aR-IN-1 | ||
C5aR-IN-1, a potent inhibitor of C5aR, is linked with the potential to research inflammatory diseases. This association is due to the elevated levels of C5a, which are connected with autoimmune and inflammatory disorders... | |||
T64200 | C5aR-IN-2 | ||
C5aR-IN-2 is a potent inhibitor of C5aR. C5aR-IN-2 has shown potential for the study of inflammatory diseases. | |||
TP1834 | MUC5AC motif peptide | ||
MUC5AC motif peptide is a 16-amino acid fragment of mucin 5. | |||
T60161 | CP-289 | Complement System | |
CP-289 is a potent C5a receptor antagonist with IC50 of 1 μM. | |||
T12506L1 | PMX 205 acetate(514814-49-4 free base) | Complement System | |
PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88). | |||
T60151 | CP-447697 | Complement System | |
CP-447697, a lipophilic C5a receptor antagonist, exhibits an IC50 of 31 nM. It is utilized in inflammation research. | |||
T8223 | Avacopan | CCX168 | Complement System |
Avacopan (CCX168) is an orally administered small-molecule C5aR ( IC50 : 0.1 nM.)antagonist that blocks the effects of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a murine model o... | |||
TP2334 | PMX 53 acetate(219639-75-5 free base) | Complement System | |
PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an ag... | |||
T9316 | JR14a | 5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride | Complement System |
JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor. | |||
T12506L | PMX 205 | Others | |
PMX 205 is an effective complement antagonist of the C5a receptor. | |||
T12506 | PMX 205 Trifluoroacetate (514814-49-4 free base) | PMX 205 Trifluoroacetate | Others |
PMX 205 Trifluoroacetate is a potent complement antagonist of C5a receptor. | |||
T73710 | PMX 205 Trifluoroacetate | ||
PMX 205 Trifluoroacetate is a potent complement C5a receptor ( C5aR ; CD88 ) antagonist. | |||
T76913 | Avdoralimab | ||
Avdoralimab (IPH 5401), a fully human IgGκ monoclonal antibody, specifically inhibits the complement C5a receptor 1 (C5aR1) by preventing its interaction with C5a. This compound is utilized in research concerning complem... | |||
T28429 | PMX-53 | PMX53,PMX 53 | |
PMX-53 is a Mas-related gene 2 (MrgX2) agonist and C5aR(CD88) antagonist. PMX-53 reduces atherosclerotic lesions in a mouse model of atherosclerosis, inhibits lung metastasis in a mouse breast cancer model, inhibits C5a-... | |||
T83669 | PMX-53 TFA | AcPhe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg],AcF-[OPdChaWR],3D53 | |
PMX-53, a macrocyclic complement 5a (C5a) peptidomimetic and C5a receptor antagonist (IC50 = 0.3 µM), effectively inhibits the C5a-induced secretion of myeloperoxidase (MPO) in isolated human polymorphonuclear leukocytes... | |||
T76958 | Vilobelimab | ||
Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component which is pivotal in causing organ dysfunction. By preventing the activation and chemotaxis of neutrop... | |||
T74551 | Avacincaptad pegol sodium | ||
Avacincaptad pegol (ARC1905), an anti-C5 RNA aptamer, prevents the cleavage of complement factor 5 (C5) into fragments C5a and C5b. It is currently under investigation for the treatment of age-related macular degeneratio... | |||
T35836 | PMX-205 (trifluoroacetate salt) | ||
PMX-205 is a cyclic hexapeptide that acts as a potent antagonist of C5a receptor (C5aR; IC50= 31 nM).1It is orally active and blocks inflammatory signaling and symptoms in animal models of colitis and allergic asthma.2,3... | |||
T74552 | Non-PEGylated/naked ARC1905 | ||
ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched ... | |||
T74650 | JPE-1375 | ||
JPE-1375, a complement C5a receptor 1 (C5aR1) antagonist, effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice, making it useful for autoimmune and infl... | |||
T77107 | Olendalizumab | ||
Olendalizumab (ALXN1007), a humanized IgG2-G4-κ antibody derived from mice, specifically targets Complement protein C5a with a binding affinity (K i) of 60 pM. This compound is designed to inhibit the complement inflamma... | |||
T79376 | SARS-CoV-2 3CLpro-IN-19 | SARS-CoV | |
SARS-CoV-2 3CLpro-IN-19 (Compound C5a), a non-covalent, non-peptide inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibits potent in vitro activity with an IC50 of 0.7 μM. It demonstrates broad-spectrum efficacy against inf... |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPY-00653 | Complement C5 Protein, Human, Recombinant (Complement C5a) | Human | E. coli |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPY-04902 | Complement C5a Protein, Mouse, Recombinant | Mouse | E. coli |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPH-03107 | Complement C5a Protein, Pig, Recombinant (His) | Sus scrofa (Pig) | Yeast |
Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, ... | |||
TMPY-05057 | Complement C5 Protein, Human, Recombinant (His & FLAG) | Human | HEK293 |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPH-01023 | C5AR1 Protein, Human, Recombinant (Cell-Free, His) | Human | in vitro E. coli expression system |
Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a. The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transm... | |||
TMPH-01022 | C5AR1 Protein-VLP, Human, Recombinant (His) | Human | HEK293 |
Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a. The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transm... | |||
TMPY-05459 | Complement C5a Protein, Mouse, Recombinant, Biotinylated | Mouse | E. coli |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPY-06814 | Complement C5 Protein, Human, Recombinant (Flag) | Human | HEK293 |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPY-03760 | CLEC5A Protein, Rhesus, Recombinant (His) | Rhesus | HEK293 |
CLEC5A, also known as MDL1 and MDL-1, is a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesio... | |||
TMPY-00648 | UNC5A Protein, Human, Recombinant (hFc) | Human | HEK293 |
The netrin-1 receptor Uncoordinated Phenotype-5A, or UNC5A, plays an important role in predicting response to DNA damage induced by chemotherapeutic drug and regulating cell death in bladder cancer. Moreover, UNC5A is cu... | |||
TMPY-00999 | UNC5A Protein, Human, Recombinant (His) | Human | HEK293 |
The netrin-1 receptor Uncoordinated Phenotype-5A, or UNC5A, plays an important role in predicting response to DNA damage induced by chemotherapeutic drug and regulating cell death in bladder cancer. Moreover, UNC5A is cu... | |||
TMPK-01205 | MDL-1/CLEC5A Protein, Human, Recombinant (hFc) | Human | HEK293 |
In C. elegans, increased lifespan in daf-2 insulin/IGF-1 receptor mutants is accompanied by up-regulation of the MDL-1 Mad basic helix-loop-helix leucine zipper transcription factor.MDL-1, like its mammalian orthologs, i... | |||
TMPK-01218 | MDL-1/CLEC5A Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 |
In C. elegans, increased lifespan in daf-2 insulin/IGF-1 receptor mutants is accompanied by up-regulation of the MDL-1 Mad basic helix-loop-helix leucine zipper transcription factor.MDL-1, like its mammalian orthologs, i... | |||
TMPH-02121 | SLC5A5 Protein, Human, Recombinant (B2M & His) | Human | E. coli |
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant ... | |||
TMPH-02120 | SLC5A5 Protein, Human, Recombinant (His) | Human | E. coli |
Mediates iodide uptake in the thyroid gland. | |||
TMPH-02119 | SLC5A2 Protein, Human, Recombinant (His & Myc) | Human | E. coli |
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.; Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affini... | |||
TMPH-03074 | UBC5A Protein, Japonica rice, Recombinant (His & Myc) | Rice | E. coli |
E2 conjugating enzyme that associates with the E3 ubiquitin-protein ligase EL5 to mediates ubiquitination of target proteins. | |||
TMPH-02032 | GPRC5A Protein, Human, Recombinant (GST) | Human | E. coli |
GPRC5A Protein, Human, Recombinant (GST) is expressed in E. coli. | |||
TMPY-03872 | CLEC5A Protein, Rat, Recombinant (His) | Rat | HEK293 |
CLEC5A, also known as MDL1 and MDL-1, is a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesio... | |||
TMPY-03928 | CLEC5A Protein, Rhesus, Recombinant (mFc) | Rhesus | HEK293 |
CLEC5A, also known as MDL1 and MDL-1, is a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesio... | |||
TMPY-06137 | Complement C5 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPH-03528 | Chemotaxis inhibitory Protein, S. aureus (strain NCTC 8325/PS47), Recombinant (His & Myc) | Staphylococcus aureus | E. coli |
Involved in countering the first line of host defense mechanisms. Specifically inhibits the response of human neutrophils and monocytes to complement anaphylatoxin C5a and formylated peptides, like N-formyl-methionyl-leu... | |||
TMPY-06538 | Complement C5 Protein, Cynomolgus, Recombinant | Cynomolgus | HEK293 |
C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathway... | |||
TMPH-03529 | Chemotaxis inhibitory Protein, S. aureus (strain MRSA252), Recombinant (His) | Staphylococcus aureus | Yeast |
Involved in countering the first line of host defense mechanisms. Specifically inhibits the response of human neutrophils and monocytes to complement anaphylatoxin C5a and formylated peptides, like N-formyl-methionyl-leu... | |||
TMPH-01773 | ELANE Protein, Human, Recombinant (GST) | Human | E. coli |
Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis. Capable of killing E.coli but not S.aureus in vitro; digests outer membrane pro... | |||
TMPH-03270 | Complement C5 Protein, Rat, Recombinant (His & Myc) | Rat | E. coli |
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the founda... | |||
TMPH-03578 | SCIN Protein, S. aureus, Recombinant (His & Myc) | Staphylococcus aureus | E. coli |
Involved in countering the first line of host defense mechanisms. Efficiently inhibits opsonization, phagocytosis and killing of S.aureus by human neutrophils. Acts by binding and stabilizing human C3 convertases (C4b2a ... | |||
TMPH-03580 | Zinc metalloproteinase aureolysin Protein, S. aureus, Recombinant (His & Myc) | Staphylococcus aureus | E. coli |
Plays an essential role in immune evasion by helping bacteria to resist complement-mediated killing by neutrophils. Inhibits the deposition of host C3b on bacterial surfaces and the release of the chemoattractant C5a by ... | |||
TMPY-00713 | CD55/DAF Protein, Human, Recombinant (hFc) | Human | HEK293 |
CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It... | |||
TMPY-06679 | CD55/DAF Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 |
CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It... | |||
TMPY-03004 | CD55/DAF Protein, Rat, Recombinant (hFc) | Rat | HEK293 |
CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It... | |||
TMPY-02616 | CD55/DAF Protein, Mouse, Recombinant (His) | Mouse | HEK293 |
CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It... | |||
TMPY-01292 | CD55/DAF Protein, Human, Recombinant (His) | Human | HEK293 |
CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It... |